AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-06-01 - American Society of Clinical Oncology Meeting - Abstract No: 3001

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

156.3 USD

Average target price

182.1 USD

Spread / Average Target

+16.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+0.86%	276B
ELI LILLY AND COMPANY	+39.82%	734B
NOVO NORDISK A/S	+32.13%	591B
JOHNSON & JOHNSON	-7.31%	350B
MERCK & CO., INC.	+14.23%	315B
ASTRAZENECA PLC	+13.92%	238B
ROCHE HOLDING AG	-6.42%	204B
NOVARTIS AG	+8.18%	206B
AMGEN INC.	+4.51%	161B
PFIZER, INC.	-2.05%	160B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-05-30 pm EDT			5-day change	1st Jan Change
156.3 ^USD	+0.98%		-1.23%	+0.86%

10:36am	AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate	MT
08:00am	AbbVie Receives Positive CHMP Opinion for Risankizumab for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	CI

AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate	04:36am	MT
AbbVie Receives Positive CHMP Opinion for Risankizumab for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	02:00am	CI
OSE Immuno: towards an evolution of the Board of Directors	May. 30	CF
AbbVie Completes Acquisition of Landos Biopharma	May. 23	MT
AbbVie Inc. completed the acquisition of Landos Biopharma, Inc. from a group of shareholders.	May. 22	CI
Strides Pharma Arm Gets US FDA's Approval for Generic Stomach Ulcer Drug	May. 22	MT
BaseLaunch announced that it has received funding from AbbVie Inc.	May. 21	CI
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	May. 17	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	May. 17
Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	May. 15
Medincell: share price falls after disappointing clinical study	May. 15	CF
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders	May. 13	MT
Medincell: share price rises on resumption of trading	May. 09	CF
Declaration of Voting Results of the AbbVie Inc	May. 08	CI
Declaration of Voting Results of the AbbVie Inc	May. 08	CI
Declaration of Voting Results of the AbbVie Inc	May. 08	CI
AbbVie Says Canadian Regulator Expands Qulipta Indication to Cover Chronic Migraine	May. 08	MT
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	May. 08	MT
Health Canada Approves QULIPTA for the Preventive Treatment of Chronic Migraine in Adults	May. 08	CI
Medincell: listing suspended pending a press release	May. 08	CF
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30	MT
Health Care Up on Growth Optimism -- Health Care Roundup	Apr. 29	DJ
BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating	Apr. 29	MT
Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196	Apr. 29	MT
Barclays Adjusts Price Target on AbbVie to $187 From $195	Apr. 29	MT